Patient Characteristics, Disease Burden, Treatment Patterns and Outcomes in Patients with Acromegaly: Real-World Evidence from the Malaysian Acromegaly Registry

被引:0
|
作者
Bidin, Mohamed Badrulnizam Long [1 ]
Khan, Abdul Mueed [2 ]
Tan, Florence Hui Sieng [3 ]
Aziz, Nor Azizah [4 ]
Ali, Norhaliza Mohd [5 ]
Kamaruddin, Nor Azmi [6 ]
Vethakkan, Shireene Ratna [7 ]
Sethi, Balraj [2 ]
Hussein, Zanariah [8 ]
机构
[1] Hosp Kuala Lumpur, Jalan Pahang, Kuala Lumpur, Malaysia
[2] Novartis Corp, M Sdn Bhd, Petaling Jaya, Selangor, Malaysia
[3] Hosp Umum Sarawak, Sarawak, Malaysia
[4] Hosp Pulau Pinang, George Town, Malaysia
[5] Hosp Sultanah Aminah Johor Bahru, Johor Baharu, Malaysia
[6] Hosp Canselor Tuanku Muhriz UKM, Kuala Lumpur, Malaysia
[7] Pusat Perubatan Univ Malaya, Kuala Lumpur, Malaysia
[8] Hosp Putrajaya, Pusat Pentadbiran Kerajaan Persekutuan,Presint 7, Putrajaya 62250, Malaysia
来源
JOURNAL OF THE ASEAN FEDERATION OF ENDOCRINE SOCIETIES | 2023年 / 38卷 / 01期
关键词
acromegaly; Malaysian registry; healthcare resource utilization; treatment outcomes; CLINICAL-PRACTICE; PREVALENCE; COMPLICATIONS; MANAGEMENT; DIAGNOSIS;
D O I
10.15605/jafes.038.01.06
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. This study aims to report the demographic features of patients with acromegaly, the disease burden, and the corresponding treatment patterns and outcomes in Malaysia. Methodology. This is a retrospective study that included patients from the Malaysian Acromegaly registry who were diagnosed with acromegaly from 1970 onwards. Data collected included patient demographics, clinical manifestations of acromegaly, biochemical results and imaging findings. Information regarding treatment modalities and their outcomes was also obtained. Results. Registry data was collected from 2013 to 2016 and included 140 patients with acromegaly from 12 participating hospitals. Median disease duration was 5.5 years (range 1.0 - 41.0 years). Most patients had macroadenoma (67%), while 15% were diagnosed with microadenoma. Hypertension (49.3%), diabetes (37.1%) and hypopituitarism (27.9%) were the most common co-morbidities for patients with acromegaly. Majority of patients had surgical intervention as primary treatment (65.9%) while 20.7% were treated medically, mainly with dopamine agonists (18.5%). Most patients had inadequate disease control after first-line treatment regardless of treatment modality (79.4%). Conclusion. This registry study provides epidemiological data on patients with acromegaly in Malaysia and serves as an initial step for further population-based studies.
引用
收藏
页码:75 / 80
页数:6
相关论文
共 50 条
  • [1] Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases
    Burton, Tanya
    Le Nestour, Elisabeth
    Bancroft, Tim
    Neary, Maureen
    PITUITARY, 2013, 16 (03) : 354 - 362
  • [2] Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis
    Fleseriu, Maria
    Barkan, Ariel
    Brue, Thierry
    Duquesne, Edouard
    Houchard, Aude
    Schneider, Maria del Pilar
    Ribeiro-Oliveira Jr, Antonio
    Melmed, Shlomo
    JOURNAL OF THE ENDOCRINE SOCIETY, 2023, 7 (10)
  • [3] Patient Characteristics, Diagnostic Delays, Treatment Patterns, Treatment Outcomes, Comorbidities, and Treatment Costs of Acromegaly in China: A Nationwide Study
    Guo, Xiaopeng
    Wang, Kailu
    Yu, Siyue
    Gao, Lu
    Wang, Zihao
    Zhu, Huijuan
    Xing, Bing
    Zhang, Shuyang
    Dong, Dong
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [4] Real-world value of cabergoline in the treatment of acromegaly
    Shimon, Ilan
    BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2024, 38 (04)
  • [5] Treatment Patterns and Economic Burden in Patients Treated for Acromegaly in the USA
    Chuang C.-C.
    Bhurke S.
    Chen S.-Y.
    Dinet J.
    Brulais S.
    Gabriel S.
    Drugs - Real World Outcomes, 2015, 2 (3) : 299 - 309
  • [6] Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience
    Salvatori, Roberto
    Maffei, Pietro
    Webb, Susan M.
    Brue, Thierry
    Loftus, Jane
    Valluri, Srinivas Rao
    Gomez, Roy
    Wajnrajch, Michael P.
    Fleseriu, Maria
    PITUITARY, 2022, 25 (03) : 420 - 432
  • [7] Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience
    Roberto Salvatori
    Pietro Maffei
    Susan M. Webb
    Thierry Brue
    Jane Loftus
    Srinivas Rao Valluri
    Roy Gomez
    Michael P. Wajnrajch
    Maria Fleseriu
    Pituitary, 2022, 25 : 420 - 432
  • [8] Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases
    Tanya Burton
    Elisabeth Le Nestour
    Tim Bancroft
    Maureen Neary
    Pituitary, 2013, 16 : 354 - 362
  • [9] Real-world evidence from a retrospective study on suicide during depression: clinical characteristics, treatment patterns and disease burden
    Wang, Han
    Lyu, Nan
    Huang, Juan
    Fu, Bingbing
    Shang, Lili
    Yang, Fan
    Zhao, Qian
    Wang, Gang
    BMC PSYCHIATRY, 2024, 24 (01)
  • [10] Patient perspectives on acromegaly disease burden: insights from a community meeting
    Shah, Shruti N.
    Yuen, Kevin C. J.
    Bonert, Vivien
    Huang, Wenyu
    Sisco, Jill
    Palaty, Chrystal
    Dancel-Manning, Kristen
    Agrawal, Nidhi
    FRONTIERS IN ENDOCRINOLOGY, 2025, 16